Metabotropic glutamate receptor 3

From WikiMD's WELLNESSPEDIA


Chemical structure of ML337, a selective mGlu3 receptor modulator.

Metabotropic glutamate receptor 3 (mGlu3) is a type of G protein-coupled receptor (GPCR) that is activated by the neurotransmitter glutamate. It is one of the eight metabotropic glutamate receptors, which are divided into three groups based on their sequence homology, signal transduction mechanisms, and pharmacological properties.

Structure[edit]

Metabotropic glutamate receptor 3 is a member of the Class C GPCR family. Like other members of this family, mGlu3 has a large extracellular domain that binds glutamate, a seven-transmembrane domain that spans the cell membrane, and an intracellular domain that interacts with G proteins. The receptor is typically found as a dimer, which is important for its function.

Function[edit]

mGlu3 receptors are primarily involved in modulating synaptic transmission and neuronal excitability. They are predominantly expressed in the central nervous system, including the cerebral cortex, hippocampus, and thalamus. Activation of mGlu3 receptors can lead to the inhibition of adenylyl cyclase, resulting in decreased levels of cyclic AMP (cAMP) and modulation of various downstream signaling pathways.

Pharmacology[edit]

The pharmacological modulation of mGlu3 receptors has been of significant interest due to their potential therapeutic applications. Selective agonists and antagonists have been developed to study the receptor's function and its role in various neurological disorders. ML337 is a selective positive allosteric modulator of mGlu3, which has been used in research to explore the receptor's potential as a drug target.

Clinical Significance[edit]

mGlu3 receptors have been implicated in several neurological and psychiatric disorders, including schizophrenia, anxiety, and depression. Modulation of mGlu3 receptor activity is being investigated as a potential therapeutic strategy for these conditions. The receptor's role in neuroprotection and neuroinflammation also makes it a target of interest in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Related pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.